Report: At 4 Billion Dollars and Growing, the Microarray Market Cannot Be Underestimated
NEW YORK, Jan. 28, 2016 /PRNewswire/ -- The world market for microarrays is estimated at $4 billion according to Kalorama Information. The healthcare market research publisher said the market includes DNA microarrays, Lab-on-a-Chip products, Protein Microarrays and others. The global microarrays market is rapidly evolving with new applications, technologies, and end-users. Newer technologies are emerging as companies are investing more on research and development to gain a competitive edge in this expanding market. DNA microarray is the most widely used diagnostic tool, and is used for tracking the behavior and pattern of diseases.
Microarrays, or biochips, are a collection of microscopic DNA spots or proteins, or other biological material, immobilized on a solid surface such as a glass slide, membrane, microtiter plate, or other solid surface. Microarrays are used to test levels of large number of genes or peptides that are arrayed in rows and columns simultaneously or to genotype multiple regions of a genome. Some can process laboratory functions on a single chip of only millimeters to a few square centimeters to achieve automation and high-throughput screening. In its latest report, The World Market for Microarrays, Kalorama said that despite the entrance of next-generation sequencing products and predictions of the demise of microarray products, a multi-billion dollar market will remain for the foreseeable future.
"In a sense, we don't think you can count microarrays out," said Bruce Carlson, Publisher of Kalorama Information. "Sequencing is exploding but at the same time, this technology has an installed base and is cost-effective in many cases."
Several life sciences areas are trending, in a helpful way, for the market for microarrays. Proteomics and Genomics are two areas driving the use of microarray products. Genomics is the study of genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes (the complete set of DNA within a single cell). This field includes trying to determine the entire DNA sequence of organisms and fine-scale genetic mapping. Proteomics studies when and where proteins are expressed, and their structure, functions, and interactions. Proteomics has broad applications in drug therapeutics and diagnostics.
Illumina, Agilent and Affymetrix are among the top names in microarrays. Santa Clara, CA-based Affymetrix was one of the pioneers and one of the largest producers of DNA microarrays, according to Kalorama. Affymetrix was recently set to be purchased by Thermo Fisher for approximately $1.3 billion.
"The recent acquisition of Affymetrix by Thermo Fisher demonstrates the industry's belief in the technology," Carlson said.
Kalorama's The World Market for Microarrays has segment market analysis for types of microarrays, geographic breakouts and forecasts to 2020. Companies are profiled in the report. The report can be obtained at: http://www.kaloramainformation.com/redirect.asp?progid=88304&productid=9618385.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/report-at-4-billion-dollars-and-growing-the-microarray-market-cannot-be-underestimated-300210688.html
SOURCE Kalorama Information